



# Influenza – the greatest master of metamorphosis-constant puzzle

L. Brydak



M. Koperny et al:

**The prevalence of combination vaccines for children in Europe. Analysis of the availability and funding.**



M. Szkultecka-Dębek et al:

**Schizophrenia and Negative Symptoms – Burden of Disease in Seven Central and Eastern European (CEE) Countries.**



Z.Voko et al:

**Mapping the cancer-specific EORTC QLQ-BR23 onto the preference-based EuroQol-5D instrument.**

# Dear Colleagues

**THE FOURTH JHPOR EDITION IS LARGELY DEVOTED TO VACCINES. WE PRESENT SOME ISSUES OF VACCINATION AGAINST INFLUENZA, WE SHOW THE AVAILABILITY AND FUNDING MECHANISMS OF COMBINATION VACCINES FROM 33 EUROPEAN COUNTRIES, AND COST-EFFECTIVENESS ANALYSIS OF HUMAN PAPILOMAVIRUS (HPV) VACCINATION AS AN EXTENSION TO THE CERVICAL CANCER PREVENTION.**

Despite the campaign for vaccination against influenza, its coverage is steadily falling, and last season it was below 5% in Poland. The reasons for varying effectiveness of influenza vaccines are complex, but nowadays it is believed, that role of genetic and environmental factors should be emphasized. Some point to the need to monitor the post-vaccination adverse events. Additionally, approach to vaccination should be personalized.

The increasing cost of clinical trials of vaccination cause the increased interest in solutions based on public-private partnership. The current and planned in the near future research projects conducted by IMI (Innovative Medicines Initiative) acting jointly with the EFPIA (European Federation of Pharmaceutical Industries and Associations) are showed in the article of A. Wittelsberger and M. Goldman.

Two articles in this issue relate to schizophrenia. The first shows the methodology of the project titled "Burden of Disease in Seven Central and Eastern European (CEE)", and the second was the analysis of the cost effectiveness of injectable atypical antipsychotics long-acting for chronic schizophrenia in Poland.

As for disease cost we present to you 2 articles. The first one shows clinical and economic analysis of non-medical technology in Russia, and the second one written by colleagues from Military Institute of Medicine in Warsaw presents assessment of direct costs of hospitalization caused by drug-induced skin reactions. Both works were presented during the earlier Russian-Polish ISPOR meetings.

Also, an analysis of rationalization, which refers to solutions in the Polish Reimbursement Act, was presented on the example of hypertension drugs.

It should be noted, that in the framework of the Polish Pharmacoeconomic Society a Polish glossary of Quality of Life related terms is currently in progress. The glossary's methodological assumptions were presented in the form of a short communication.

The next edition of JHPOR will be dedicated to the challenges in monoclonal antibody-based therapies. At the same time I cordially invite all interested to the 1st JHPOR Conference titled "Safety Aspects of Monoclonal Antibodies and Fusion Proteins Treatment", which will be held on March 15th, 2014, in Warsaw.

*We wish you pleasant reading of our journal*

Editor-in-Chief      Deputy Editor-in-Chief  
Prof. K. Jahnz-Różyk      Dr J. Lis

## General Editorial Policies

Journal of Health Policy & Outcomes Research (JHPOR) is pre-reviewed, international scientific journal, publishing the work of an important contribution to the development of pharmacoconomics and outcomes research in Poland and worldwide. The journal is issued under the auspices of the Polish Society of Pharmacoconomics. The journal is published twice a year in electronic form, optionally in the paper version.

### Topics of publications includes the following issues:

Clinical Trials (Phase 1-4)  
Health-Related Quality of Life  
Patient-Reported Outcomes (PRO)  
Health Technology Assessment  
Pharmacoconomics Analyses  
Comparative Effectiveness Research  
Health Policy Analysis in Poland and around the World  
Budget Impact Analyses  
Decision Making and Management in Health Care  
Health Insurance

### Editor-in-Chief

Prof. Karina Jahnz-Różyk  
Military Institute of Medicine

### Deputy Editor-in-Chief

Dr Joanna Lis  
Medical University of Warsaw  
Sanofi Group

### Publisher

Fundacja Pro-Medicina  
www.promedicina.pl

### Office

Marta Warchol  
Aneta Wójcikowska  
office@jhpore.com

## JHPOR – ISSUE 3

- 1 From the editors - K. Jahnz-Różyk
- 2 Influenza – the greatest master of metamorphosis – constant puzzle - Lidia Brydak
- 3 Public-private collaboration to advance the development and benefit-risk assessment of vaccines: The Innovative Medicines Initiative - Angela Wittelsberger, Michel Goldman
- 4 The prevalence of combination vaccines for children in Europe. Analysis of the availability and funding - Magdalena Koperny, Agnieszka Kargul, Michał Seweryn, Rafał Niżankowski
- 5 Cost-effectiveness analysis of Human Papillomavirus (HPV) vaccination using Cervarix® as an extension to the cervical cancer prevention programme in Poland - Katarzyna Wepięć, Magdalena Mrożek-Gąsiorowska, Marcin Gąsiorowski, Oskar Pankiewicz, Andrzej Nowakowski
- 6 Schizophrenia and negative symptoms – burden of disease in seven Central and Eastern European (CEE) countries. Literature review and retrospective data collection – project design and rationale - Monika Szkulciecka-Dębek, Jacek Walczak, Joanna Augustyńska, Izabela Pieniążek, Grażyna Dębowska, Katarzyna Miernik
- 7 Cost-effectiveness of injectable atypical long-acting antipsychotics for chronic schizophrenia in Poland - Michiel E. H. Hemels, Thomas R. Einarson, Roman Zilbershtein, Agata Schubert, Iwona Skrzekowska-Baran, Kristel Van Impe
- 8 Clinical and economic analysis of non-medical technologies in Russia - Malwina Holownia, Pavel Vorobiev, Lubov Krasnova, Ludmila Bezmelnitsina
- 9 Analysis of direct costs of drug-induced skin reactions treatment considering DRG classification in the perspective of medical service provider and public payer - Nina Wiśniewska, Elwira Beata Paluchowska, Witold Owczarek, Monika Szkulciecka-Dębek, Karina Jahnz-Różyk
- 10 How to optimize public spending on antihypertensive treatment in Poland - an example of rationalization analysis - Tomasz Hermanowski, Łukasz Borowiec, Tomasz Faluta
- 11 Mapping the cancer-specific EORTC QLQ-BR23 onto the preference-based EuroQol-5D instrument - Zoltan Voko, Renata Nemeth, Magdolna Dank, Zsófia Nagy-Erdei, Zoltan Kalo, Lajos Geczi
- 12 Methodology and development of the Polish Dictionary of Quality of Life Terms - Dominik Golicki, Michał M. Farkowski, Patrycja Grabowska-Krawiec, Monika Szkulciecka-Dębek, Szymon Zawodnik, Łukasz Borowiec, Marcin Czech
- 13 Polish Pharmacoeconomic Society activities review 2/2013 - Monika Szkulciecka-Dębek